Urgent reconsideration of lung edema as a preventable outcome in COVID-19: Inhibition of TRPV4 represents a promising and feasible approach

TRPV4 Protects the Lung from Bacterial Pneumonia via MAPK Molecular Pathway Switching

(2020) Rachel G. Scheraga et al.   JOURNAL OF IMMUNOLOGY

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects

(2019) Navin Goyal et al.   American Journal of Cardiovascular Drugs

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)

(2019) Carl A. Brooks et al.   ACS Medicinal Chemistry Letters

TRPV4 Is Required for Hypoxic Pulmonary Vasoconstriction

(2015) Neil M. Goldenberg et al.   ANESTHESIOLOGY

TRPV4 Mechanosensitive Ion Channel Regulates Lipopolysaccharide-Stimulated Macrophage Phagocytosis

(2015) Rachel G. Scheraga et al.   JOURNAL OF IMMUNOLOGY

TRPV4: physiological role and therapeutic potential in respiratory diseases

(2014) Neil M. Goldenberg et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY